5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details
臨床試験数 : 95 / 薬物数 : 119 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00211224 (ClinicalTrials.gov) | April 2000 | 13/9/2005 | Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) | Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes) | Multiple System Atrophy;Progressive Supranuclear Palsy | Drug: Riluzole | King's College London | Assistance Publique - Hôpitaux de Paris;University of Ulm;Aventis Pharmaceuticals | Terminated | 30 Years | 80 Years | Both | 800 | Phase 3 | United Kingdom |